CoChat
Sign Up
Cited by 974Parkinson's Disease Mechanisms and TreatmentsGastrointestinal motility and disordersGut microbiota and health

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease

Open access
Forsyth, Christopher B., Shannon, Kathleen M., Kordower, Jeffrey H., Voigt, Robin M., Shaikh, Maliha, Jaglin, Jean A., Estes, Jacob D., Dodiya, Hemraj B., Keshavarzian, Ali·2011·PLoS ONE
DOI 10.1371/journal.pone.0028032PMC PMC3228722
Open this paper in CoChat — free accountOpen PDF

Abstract

UNLABELLED: Parkinson's disease (PD) is the second most common neurodegenerative disorder of aging. The pathological hallmark of PD is neuronal inclusions termed Lewy bodies whose main component is alpha-synuclein protein. The finding of these Lewy bodies in the intestinal enteric nerves led to the hypothesis that the intestine might be an early site of PD disease in response to an environmental toxin or pathogen. One potential mechanism for environmental toxin(s) and proinflammatory luminal products to gain access to mucosal neuronal tissue and promote oxidative stress is compromised intestinal barrier integrity. However, the role of intestinal permeability in PD has never been tested. We hypothesized that PD subjects might exhibit increased intestinal permeability to proinflammatory bacterial products in the intestine. To test our hypothesis we evaluated intestinal permeability in subjects newly diagnosed with PD and compared their values to healthy subjects. In addition, we obtained intestinal biopsies from both groups and used immunohistochemistry to assess bacterial translocation, nitrotyrosine (oxidative stress), and alpha-synuclein. We also evaluated serum markers of endotoxin exposure including LPS binding protein (LBP). Our data show that our PD subjects exhibit significantly greater intestinal permeability (gut leakiness) than controls. In addition, this intestinal hyperpermeability significantly correlated with increased intestinal mucosa staining for E. coli bacteria, nitrotyrosine, and alpha-synuclein as well as serum LBP levels in PD subjects. These data represent not only the first demonstration of abnormal intestinal permeability in PD subjects but also the first correlation of increased intestinal permeability in PD with intestinal alpha-synuclein (the hallmark of PD), as well as staining for gram negative bacteria and tissue oxidative stress. Our study may thus shed new light on PD pathogenesis as well as provide a new method for earlier diagnosis of PD and suggests potential therapeutic targets in PD subjects. TRIAL REGISTRATION: Clinicaltrials.gov NCT01155492.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0028032

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Consort 2010 flow diagram of this study. 12 research subjects were invited to participate in this study. Two were excluded because they failed to meet inclusion criteria (prohibited medications). One study subject incorrectly performed the 24-hour urine collection for intestinal permeability testing and his data were excluded from analysis. Nine study subjects completed all study assessments.
Figure 1 Consort 2010 flow diagram of this study. 12 research subjects were invited to participate in this study. Two were excluded because they failed to meet inclusion criteria (prohibited medications). One study subject incorrectly performed the 24-hour urine collection for intestinal permeability testing and his data were excluded from analysis. Nine study subjects completed all study assessments.CC BY · PubMed Central
Figure 2 Intestinal permeability to lactulose and mannitol is similar in control and PD subjects. PD subjects and healthy controls were assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samples as described in Materials and Methods. Urinary lactulose and mannitol as well as the L/M ratio (all primarily measures of small intestinal permeability) were not significantly different in PD patients compared to controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours ± SE. * p<0.05.
Figure 2 Intestinal permeability to lactulose and mannitol is similar in control and PD subjects. PD subjects and healthy controls were assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samples as described in Materials and Methods. Urinary lactulose and mannitol as well as the L/M ratio (all primarily measures of small intestinal permeability) were not significantly different in PD patients compared to controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours ± SE. * p<0.05.CC BY · PubMed Central
Figure 3 Intestinal permeability to sucralose is significantly greater in PD patients. PD subjects and healthy controls were assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samples as described in Materials and Methods. Urinary sucralose, a measure of whole intestine permeability, was significantly greater in PD subjects vs. healthy age matched controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours ± SE. * p<0.05.
Figure 3 Intestinal permeability to sucralose is significantly greater in PD patients. PD subjects and healthy controls were assessed for intestinal permeability using an oral sugar solution containing sucrose, lactulose, mannitol, and sucralose and GC analysis of 24 hour urine samples as described in Materials and Methods. Urinary sucralose, a measure of whole intestine permeability, was significantly greater in PD subjects vs. healthy age matched controls. Data are presented as mean % urinary excretion of the oral dose in 24 hours ± SE. * p<0.05.CC BY · PubMed Central
Figure 4 Plasma LBP is significantly lower in PD patients. Plasma levels of LPS binding protein (LBP), an indirect measure of systemic endotoxin exposure, were determined for PD subjects and healthy controls as described in Materials and Methods. Values for plasma LBP in PD subjects were significantly lower than in healthy controls. Data are presented as means (ng/ml) ± SE. *p<0.05.
Figure 4 Plasma LBP is significantly lower in PD patients. Plasma levels of LPS binding protein (LBP), an indirect measure of systemic endotoxin exposure, were determined for PD subjects and healthy controls as described in Materials and Methods. Values for plasma LBP in PD subjects were significantly lower than in healthy controls. Data are presented as means (ng/ml) ± SE. *p<0.05.CC BY · PubMed Central
Figure 5 Immunohistochemical staining of intestinal biopsies for E. coli, α-synuclein, and 3-NT is significantly greater in PD subjects. Intestinal biopsies from PD subjects and healthy controls were formalin fixed, paraffin embedded, and then cut to 5 µm and processed as described in Materials and Methods for each respective antibody to either E.coli gram negative bacteria (A,D,G), α-synuclein (B,E,H) or 3-nitrotyrosine (3-NT)(C,F,I). Representative images are shown from a PD subject at 15× (A–C) and 40× (D–F) magnification using the same field of view and from a healthy control subject (G–I) at 40×. Staining data were analyzed by blinded observers and PD subjects were found to stain significantly greater for E. coli, α-synuclein, and 3-NT. Scale bars = A–C 50 µm, D–I 100 µm.
Figure 5 Immunohistochemical staining of intestinal biopsies for E. coli, α-synuclein, and 3-NT is significantly greater in PD subjects. Intestinal biopsies from PD subjects and healthy controls were formalin fixed, paraffin embedded, and then cut to 5 µm and processed as described in Materials and Methods for each respective antibody to either E.coli gram negative bacteria (A,D,G), α-synuclein (B,E,H) or 3-nitrotyrosine (3-NT)(C,F,I). Representative images are shown from a PD subject at 15× (A–C) and 40× (D–F) magnification using the same field of view and from a healthy control subject (G–I) at 40×. Staining data were analyzed by blinded observers and PD subjects were found to stain significantly greater for E. coli, α-synuclein, and 3-NT. Scale bars = A–C 50 µm, D–I 100 µm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 3

  1. K Shannon, 2011, Alpha-synuclein in Colonic Submucosa in Early Untreated Parkinson Disease., Movement Disorders
  2. WJ Kupsky, 1987, Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells., Neurology, 37, 1253, 10.1212/WNL.37.7.1253 · DOI
  3. K Wakabayashi, 1997, Neuropathology of autonomic nervous system in Parkinson's disease., Eur Neurol, 38, 2, 10.1159/000113469 · DOI

Cited by

Sorted by citations

Items 101–131 of 131

Metadata

Authors
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A.
Affiliations
  • Rush University Medical Center (US)
  • National Cancer Institute (US)
Corresponding author
Forsyth, Christopher B.
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2011-12-01
Volume
6
Issue
12
Pages
e28032
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0028032
PMC
PMC3228722
OpenAlex
W1992780204
Cited by
974
References
48
Citations by year
2026: 72 · 2025: 73 · 2024: 86 · 2023: 108 · 2022: 108 · 2021: 132 · 2020: 96 · 2019: 72 · 2018: 66 · 2017: 44 · 2016: 33 · 2015: 36 · 2014: 20 · 2013: 13 · 2012: 14
FWCI
9.55
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Parkinson's Disease Foundation
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
Parkinson's disease, intestinal permeability, alpha-synuclein, Lewy bodies, endotoxin exposure, bacterial translocation, nitrotyrosine, oxidative stress, LPS-binding protein, Escherichia coli, intestinal barrier integrity, early diagnosis, gut-brain axis
MeSH terms
Lipopolysaccharide-Binding Protein, Acute-Phase Proteins, Aged, Carrier Proteins, Endotoxins, Escherichia coli, Escherichia coli Infections, Female, Humans, Immunoenzyme Techniques, Intestinal Mucosa, Intestines, Male, Membrane Glycoproteins, Middle Aged, Neurons, Parkinson Disease, Permeability, Sucrose, Tyrosine, Biomarkers, Oxidative Stress, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review